Clinical Trial Search

Primary: Overall Response Rate (Phase II) — 0; 0; 0; 0 participants

Primary: Number of Participants With Serious and Non-Serious Adverse Events — 257 participants

Primary: Progression Free Survival — 1.87; 2.04 years — p=0.76

Primary: Change in Visceral and Subcutaneous Abdominal Adipose Tissue Over 6 Months — 57; 799; -111; 3634 mm^2 — p=0.70

Primary: Change in Morning Peak Expiratory Flow (PEF) From Baseline to the Treatment Period Average — 4.1; 17.8 liters/minute — p=<0.0001

Primary: Percent Change in Median pS6K1 Immunostaining Among Participants With Barrett Esophagus — 1.4; -14.7 percentage of change — p=0.7981

Primary: Number of Participants With a Best Overall Response (OR) of Confirmed Complete Response (CR) or Partial Response (PR), as Assessed by the Independent Review Committee…

Primary: Complete Response Rate to Induction Therapy — 64 percentage of participants

Primary: Progression-free Survival at 6 Months — 20.6 percentage of participants

Primary: Number of Participants With Adverse Events (AEs) — 21; 35; 2; 9 participants

Primary: Dose of Arsenic That Blocks Activation of p53 — 0.005 mg/kg

Primary: Objective Tumor Response (Defined as Partial [PR] or Complete Response [CR] by RECIST Criteria) — 0 participants

Primary: Number of Participants With Adverse Events — 7; 9; 9; 6 participants

Primary: Change From Baseline in Percent-predicted Forced Vital Capacity (FVC) at Week 16 — 2.02; 1.15; -0.15 percent of predicted FVC — p=0.543

Primary: Progression-free Survival at 6 Months — 6.5 percentage of participants